NCT04735627 is a NA clinical trial of Levodopameter in Parkinson Disease, sponsored by University of California, San Diego.

Who is sponsoring NCT04735627?

NCT04735627 is sponsored by University of California, San Diego.

What drugs are being tested in NCT04735627?

Interventions in NCT04735627: Levodopameter.

What condition does NCT04735627 study?

NCT04735627 studies Parkinson Disease.

Is NCT04735627 still recruiting?

NCT04735627 is currently recruiting now. Last updated 10 February 2025.

Last reviewed 2025-02-10 · How we verify

NCT04735627

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real-Time Levodopa Monitoring for Improved Management of Parkinson Disease

Recruiting now NA Last updated 10 February 2025

What this trial tests

NA trial testing Levodopameter in Parkinson Disease in 20 participants. Currently enrolling.

Timeline

7 December 2021

Primary endpoint
1 December 2027

1 February 2028

Quick facts

Lead sponsor	University of California, San Diego
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	20
Start date	7 December 2021
Primary completion	1 December 2027
Estimated completion	1 February 2028
Sites	1 location across United States

Drugs / interventions tested

Levodopameter

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

University of California, San Diego

Who can join

Adults 40 to 85, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Levodopa Levels
Time frame: through study completion, an average of 12 months
Data analysis from this first-of-its-kind microneedle levodopa monitoring device is necessarily exploratory and descriptive. We will assess the Levodopameter's feasibility and accuracy by comparing its interstitial fluid levodopa measurements to plasma levodopa levels analyzed by high-performance liquid chromatography.

Sponsor's own description

This project aims to develop a minimally invasive sensor device to monitor levodopa levels in real time. We will test the accuracy, tolerability, and safety of this device in people with Parkinson disease.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Microneedle Sensors for Point-of-Care Diagnostics.
Hu Y, Chatzilakou E, Pan Z, Traverso G, et al · · 2024 · cited 67× · PMID 38225744 · DOI 10.1002/advs.202306560
Polymeric Microneedles for Health Care Monitoring: An Emerging Trend.
Pereira RL, Vinayakumar KB, Sillankorva S. · · 2024 · cited 23× · PMID 38654679 · DOI 10.1021/acssensors.4c00612
Microneedle sensors for dermal interstitial fluid analysis.
Kim G, Ahn H, Chaj Ulloa J, Gao W. · · 2024 · cited 19× · PMID 39363915 · DOI 10.1007/s44258-024-00028-0
From mechanism to applications: Advanced microneedles for clinical medicine.
Yang Y, Sun H, Sun X, Wang Y, et al · · 2025 · cited 9× · PMID 40463395 · DOI 10.1016/j.bioactmat.2025.04.025
Biosensor Strip for Rapid On-site Assessment of Levodopa Pharmacokinetics along with Motor Performance in Parkinson's Disease.
Mahato K, Moon JM, Moonla C, Longardner K, et al · · 2024 · cited 8× · PMID 38682251 · DOI 10.1002/anie.202403583
Acute Pharmacodynamic Effects of Oral Levodopa on Blood Pressure in Parkinson's Disease.
Longardner K, Liu C, Momper J, Mahato K, et al · · 2025 · cited 2× · PMID 41031701 · DOI 10.1002/phar.70066
Body Biofluids for Minimally-Invasive Diagnostics: Insights, Challenges, Emerging Technologies, and Clinical Potential.
Rao LT, Mandal CK, Patolsky F. · · 2026 · cited 1× · PMID 41074254 · DOI 10.1002/adhm.202503096

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other University of California, San Diego trials

Trials by the same sponsor.

NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04735627 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 10 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04735627.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing